Evidence map›Paper›PMID 35133639›Full record

ReviewDrugs2022

Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.

Elizabeth M Burnette, Steven J Nieto, Erica N Grodin, Lindsay R Meredith, Brian Hurley, Karen Miotto, Artha J Gillis, Lara A Ray

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 8 pooled it
22.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 8 syntheses or guidelines pooled it, 153 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Baclofen for alcohol use disorder.The Cochrane database of systematic reviews · 2023
    Pooled it
  8. Guideline
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Major depressive disorder-alcohol use disorder comorbidity: diagnosis, mechanisms and treatment.European archives of psychiatry and clinical neuroscience · 2026
    Review
  17. Review
  18. Article
  19. Article
  20. Review

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Elizabeth M BurnetteDepartment of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.ORCID http://orcid.org/0000-0003-4005-5885
Steven J NietoDepartment of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Erica N GrodinDepartment of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Lindsay R MeredithDepartment of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Brian HurleyDepartment of Public Health, Los Angeles County, CA, USA.
Karen MiottoDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Artha J GillisDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Lara A RayDepartment of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA. lararay@psych.ucla.edu.
University of California, Los Angeles · USLos Angeles County Department of Public Health · US

Funding

Clinical Neuroscience of Alcoholism: Integrating Neuroscience and Clinical TrialsK24AA025704 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY · 2018 to 2026
$1.3M
Applying behavioral economics to screen medications for alcohol use disorderF32AA029288 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NIETO, STEVEN J · 2021 to 2022
$115k
Probing Inflammation and Reward Sensitivity in Alcohol Use DisorderF31AA028976 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BURNETTE, ELIZABETH · 2020 to 2022
$103k
NIAAA NIH HHS F31 AA028976NIAAA NIH HHS F31AA028976NIAAA NIH HHS F32 AA029288NIAAA NIH HHS F32AA029288NIAAA NIH HHS K24 AA025704NIAAA NIH HHS K24AA025704
6 · The paper itself

Abstract

Alcohol use disorder (AUD) is a highly prevalent but severely under-treated disorder, with only three widely-approved pharmacotherapies. Given that AUD is a very heterogeneous disorder, it is unlikely that one single medication will be effective for all individuals with an AUD. As such, there is a need to develop new, more effective, and diverse pharmacological treatment options for AUD with the hopes of increasing utilization and improving care. In this qualitative literature review, we discuss the efficacy, mechanism of action, and tolerability of approved, repurposed, and novel pharmacotherapies for the treatment of AUD with a clinical perspective. Pharmacotherapies discussed include: disulfiram, acamprosate, naltrexone, nalmefene, topiramate, gabapentin, varenicline, baclofen, sodium oxybate, aripiprazole, ondansetron, mifepristone, ibudilast, suvorexant, prazosin, doxazosin, N-acetylcysteine, GET73, ASP8062, ABT-436, PF-5190457, and cannabidiol. Overall, many repurposed and novel agents discussed in this review demonstrate clinical effectiveness and promise for the future of AUD treatment. Importantly, these medications also offer potential improvements towards the advancement of precision medicine and personalized treatment for the heterogeneous AUD population. However, there remains a great need to improve access to treatment, increase the menu of approved pharmacological treatments, and de-stigmatize and increase treatment-seeking for AUD.

Indexed as

Alcohol DeterrentsAlcoholismAcamprosateBaclofenDisulfiramHumansNaltrexoneTopiramateAcamprosateAlcohol DeterrentsBaclofenDisulfiramNaltrexoneTopiramate

Identifiers

PMID35133639
PMCPMC8888464
OpenAlexW4210944481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.